High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents

Evangelos Terpos; Meletios A Dimopoulos; Vikas Shrivastava; Kim Leitzel; Dimitrios Christoulas; Magdalini Migkou; Maria Gavriatopoulou; Konstantinos Anargyrou; Peter Hamer; Efstathios Kastritis; Walter P. Carney; Allan Lipton

doi:10.1016/j.leukres.2009.08.035

Related publications

Article2009

A014 High Serum TIMP-1 Correlates with Advanced Myeloma and Poor Survival

Evangelos Terpos, Meletios A Dimopoulos, Vikas Shrivastava, Kim Leitzel, D. Christoulas, Magdalini Migkou, Maria Gavriatopoulou, Konstantinos Anargyrou, Efstathios Kastritis, Philip C. De Witt Hamer, W. P. Carney, Allan Lipton

Article2009

Diffuse MRI Marrow Pattern Correlates with Increased Angiogenesis, Advanced Disease Features and Poor Prognosis in Newly-Diagnosed Patients with Multiple Myeloma Treated with Novel Agents.

Lia A. Moulopoulos, Evangelos Terpos, Dimitrios Christoulas, Efstathios Kastritis, Dimitra Anagnostou, Ανδρέας Κουρέας, Μαρία Ρούσσου, Maria Gavriatopoulou, Magdalini Migkou, Marina Iakovaki, Μαρία Γκοτζαμανίδου, Vasilios Skiadas, Anna Tasidou, Meletios A Dimopoulos

Article2010

Elevated Levels of Circulating Activin-A Correlate with Features of Advanced Disease, Extensive Bone Involvement and Inferior Survival In Patients with Multiple Myeloma

Evangelos Terpos, Dimitrios Christoulas, Efstathios Kastritis, Μαρία Γκοτζαμανίδου, Maria Gavriatopoulou, Evangelos Eleutherakis‐Papaiakovou, Magdalini Migkou, Μαρία Ρούσσου, Αθανάσιος Παπαθεοδώρου, Meletios A Dimopoulos

Article2009

High Serum Sclerostin Correlates with Advanced Stage, Increased Bone Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma.

Evangelos Terpos, Dimitrios Christoulas, Eirini Katodritou, Cornelia Bratengeier, Brigitte Lindner, Silvia Harmelin, Gerhard Hawa, Georgios Boutsikas, Magdalini Migkou, Maria Gavriatopoulou, Eurydiki Michalis, Anastasia Pouli, Efstathios Kastritis, Konstantinos Zervas, Meletios A Dimopoulos

Article2011

Short progression‐free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent‐based therapy

Magdalini Migkou, Efstathios Kastritis, Μαρία Ρούσσου, Μαρία Γκοτζαμανίδου, Maria Gavriatopoulou, Nikitas Nikitas, Despina Mparmparoussi, Charis Matsouka, Dimitra Gika, Evangelos Terpos, Meletios A Dimopoulos

High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents

Discussion(0)

Related publications

A014 High Serum TIMP-1 Correlates with Advanced Myeloma and Poor Survival

Diffuse MRI Marrow Pattern Correlates with Increased Angiogenesis, Advanced Disease Features and Poor Prognosis in Newly-Diagnosed Patients with Multiple Myeloma Treated with Novel Agents.

Elevated Levels of Circulating Activin-A Correlate with Features of Advanced Disease, Extensive Bone Involvement and Inferior Survival In Patients with Multiple Myeloma

High Serum Sclerostin Correlates with Advanced Stage, Increased Bone Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma.

Short progression‐free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent‐based therapy